Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound?

Exact Sciences

Teladoc

Twist Bioscience Corp

They're well below peak levels set earlier this year. But they could be huge winners over the long run.

4 Unstoppable Healthcare Stocks to Buy on the Dip

CRISPR Therapeutics is innovating the treatment of serious diseases by pioneering gene editing to produce therapeutics. Its programs include Hemoglobinopathies, Immune-Oncology, Regenerative Medicine and more. The company is in pre-revenue stages, with sales currently coming only from upfront payments on partnerships. The market's excitement around CRISPR's technology is strong.

Crispr Therapeutics: Pullback Has Created Opportunity

Cerecor

Horizon Pharma

Johnson & Johnson

Eli Lilly

Schrodinger 

Takeda Pharmaceutical

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared first on InvestorPlace.

7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage

CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European Hematology Association (EHA) 2021 Virtual Congress.

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

Nkarta, Inc.

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide profits, 50/50.

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

One company is setting itself apart in a crowded field.

With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market

BioNTech SE

Loncar China Biopharma ETF

Loncar Cancer Immunotherapy ETF

CureVac B.V

Editas Medicine

iShares Nasdaq Biotechnology ETF

Moderna

Pfizer

Telesis Bio Inc

SPDR S&P Biotech ETF

Here is what you should know about investing in these life changing technologies.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a virtual format from June 4 to 8, 2021.

CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.

CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y

- Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)-

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

Skyworks Solutions

The Nasdaq gained ground to start the week.

Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward

Axsome Therapeutics

uniQure

Voyager Therapeutics

Reviva Pharmaceuticals

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session.

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today

In recent years, gene therapy and gene editing are growing in prominence. Leading the gene-editing innovation, CRISPR Therapeutics is poised to make history in this space. The latest data for the sickle cell disease and beta-thalassemia franchises are extremely robust.

Crispr Therapeutics: Strong Partnership And Data Development

BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) --  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 was previously granted PRIME designation for the treatment of sickle cell disease (SCD) in 2020.

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

Shopify

Both of these stocks have struggled in recent weeks, which means it might be a good time to initiate a position.

2 Unstoppable Cathie Wood Stocks That Could Make You Rich

Crispr Therapeutics: Pipeline Catalyst Triggering Upside

KalVista Pharma

Syndax Pharmaceuticals

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Rises On Gene Editing Therapy Pact With Vertex: CRISPR announced an amended collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) with respect to CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease and transfusion-dependent beta-thalassemia.

Why Crispr, KalVista And Syndax Are Moving Today

- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

CRISPR Therapeutics stock reached a 52-week high of $220.20 in Jan 2021 and has since fallen significantly down to $114.39 as of Apr 12, 2021.

CRISPR Therapeutics: A Speculative Play On The Future Of Medicine

Intellia Therapeutics

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

CRISPR Therapeutics AG (CRSP) Presents at 20th Annual Needham Virtual Healthcare Conference (Transcript)

ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company's allogeneic chimeric antigen receptor T cell (CAR-T) program at the American Association for Cancer Research (AACR) Annual Meeting 2021. The data, presented today in an e-poster session entitled, CD70 knockout: A novel approach to augment CAR-T cell function, found that the generation of CAR-T cells including knockout of the CD70 show improved properties including potency and persistence over CAR T cells where the CD70 gene remains intact.

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

AbbVie

ACADIA Pharma

Alexion Pharma

AstraZeneca

Biogen

Illumina

Kadmon Hlds

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

News for CRISPR Therapeutics Stock (CRSP)